جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

26 مُخرَج نتائج البحث عن «binding energy»

مقالوصول مفتوح20264استشهاد· Semantic Scholar

Synthesis, biological evaluation and in silico studies of novel propargyl-tethered isatin hydrazones as monoamine oxidase inhibitors for Parkinson’s disease

Scientific Reports · مجلد 16 (1)

Neurodegenerative disorders such as Parkinson’s disease are closely associated with dysregulated activity of monoamine oxidase-B (MAO-B), which leads to dopamine depletion and oxidative stress. Despite the availability of numerous monoamine oxidase (MAO) inhibitors on the market, their irreversibility and associated side effects necessitate the development of more effective and reversible MAO-B inhibitors. In this study, a series of twenty-one indole-based derivatives (PSH1 - PSH21) , collectively designated as PSH , was synthesised and evaluated for inhibitory activity against MAO isoforms. Most synthesised compounds showed higher inhibitory activity toward MAO-B than MAO-A, indicating selectivity for MAO-B. Among the PSH derivatives, PSH18 exhibited the most potent MAO-B inhibitory activity (IC 50 = 0.95 ± 0.02 µM), followed by PSH6 ( IC 50 = 1.79 ± 0.40 µM) and PSH2 (IC 50 = 1.96 ± 0.08 µM). Compound PSH18 showed the highest selectivity index value of 42.11, followed by PSH6 (22.35) and PSH2 (20.41). Additionally, PSH18 was confirmed to be a competitive and reversible inhibitor of MAO-B with an inhibition constant value of 0.89 ± 0.035 µM. Notably, PSH18 exhibited good permeability across the blood–brain barrier in parallel artificial membrane permeability assay experiments, along with acceptable absorption, distribution, metabolism, excretion, and toxicity parameters predicted through in silico modelling, suggesting its potential as a central nervous system-targeted molecule. Molecular docking and a 200 ns molecular dynamics simulation demonstrated stable binding of the ligand to the MAO-B active-site pocket, driven by hydrophobic and π–π stacking interactions with key amino acid residues lining the aromatic cage. Moreover, the calculated binding energy indicated strong ligand–protein interactions. Overall, these results indicate that the PSH scaffold could serve as a promising lead structure for the development of potent and selective MAO-B inhibitors. These compounds may have therapeutic potential for the treatment of neurodegenerative diseases.

monoamine oxidase B inhibitorsParkinson's diseaseblood-brain barrier permeabilityADME prediction
مقالوصول مفتوح202511استشهاد· Semantic Scholar

Aotaphenazine, a rare hydrophenazine, targets topoisomerase II with anticancer efficacy: In silico to in vitro evidence

PLoS ONE · مجلد 20 (12) · e0338135-e0338135

BACKGROUND: Topoisomerase II (Topo II) remains a validated target for anticancer therapy, with many clinically used agents acting via DNA intercalation and enzyme inhibition. However, their clinical use is limited by severe toxicity and resistance. In this study, we investigate aotaphenazine, a rare hydrophenazine derivative isolated from Streptomyces sp. IFM 11694 as a potential novel Topo II inhibitor with selective anticancer activity. METHODS: Molecular docking and 400 ns molecular dynamics (MD) simulations were employed to evaluate aotaphenazine's binding mode within the DNA-Topo II complex (PDB: 3QX3). MM-GBSA calculations quantified interaction energetics, while ProLIF and PLIP analyses detailed the interaction patterns. Topo II inhibition was assessed via in vitro enzymatic assays. Cytotoxicity (MTT) assays were conducted against a panel of human cancer and normal cell lines. Flow cytometry was used to evaluate apoptosis and cell cycle progression in MDA-MB-231 cells. RESULTS: aotaphenazine demonstrated a docking binding energy of -19.12 kcal/mol and remained stably intercalated within the DNA groove during MD simulations. MM-GBSA analysis showed a total binding free energy of -29.81 kcal/mol, driven primarily by van der Waals forces. Interaction profiling identified consistent π-stacking with Cyt8 and Thy9, and strong binding contributions from Ade12 and Gua13. Enzymatic assays confirmed Topo II inhibition with an IC50 of 45.01 nM, comparable to doxorubicin (30.16 nM). In vitro cytotoxicity analysis revealed moderate activity across cancer cell lines (IC50 = 26.30-54.35 µM) and significantly reduced toxicity in normal WI-38 and WISH cells (IC50 = 69.86 µM and 84.72 µM, respectively). Flow cytometry showed that aotaphenazine induced early (20.98%) and late apoptosis (42.80%), along with S-phase cell cycle arrest (43.99%) and a marked reduction in the G2/M population in MDA-MB-231 cells. CONCLUSION: aotaphenazine exhibits a compelling combination of Topo II inhibition, DNA intercalation, and selective anticancer activity, supported by both computational modeling and biological validation. Its lower cytotoxicity toward normal cells and ability to induce apoptosis and cell cycle arrest suggest strong therapeutic potential. These findings establish aotaphenazine as a promising lead compound for the development of safer and more selective Topo II-targeting anticancer agents.

topoisomerase II inhibitionDNA intercalationanticancer activitynatural product isolation
مقالوصول مغلق20253استشهاد

VEGFR-2-Targeted Semisynthetic Theobromine Derivative: A Computer-Aided Drug Design (CADD) Approach

Journal of Computational Biophysics and Chemistry · مجلد 25 (11) · 2043-2063

Angiogenesis plays a pivotal role in tumor progression, and VEGFR-2 is a well-established therapeutic target in cancer treatment. In this study, we report the design, semi-synthesis, and comprehensive evaluation of a novel theobromine-based VEGFR-2 inhibitor, T-1-BHEPA [([Formula: see text]-[Formula: see text]-(4-(1-(2-benzoylhydrazono)ethyl)phenyl)-2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1[Formula: see text]-purin-1-yl)acetamide]. A structure-based computer-aided drug design (CADD) approach was employed, beginning with pharmacophore modeling, followed by in-depth computational validation. The binding affinity of T-1-BHEPA to VEGFR-2 was examined through molecular docking, 400 ns molecular dynamics (MD) simulations, MM-GBSA binding energy calculations, and protein–ligand interaction fingerprinting (ProLIF) interaction analysis, all of which confirmed a strong and stable interaction with the VEGFR-2 active site. DFT calculations indicated T-1-BHEPA’s stability and reactivity. Before semi-synthesis, in silico ADMET evaluations highlighted good solubility, nonhepatotoxicity, low CYP2D6 interaction and noncarcinogenic potential, along with a favorable chronic toxicity profile. Consistent with these predictions, T-1-BHEPA exhibited potent in vitro VEGFR-2 inhibition (IC 50 [Formula: see text] 0.059 ± 0.006 [Formula: see text]M), comparable to sorafenib (IC 50 [Formula: see text] 0.045 ± 0.006 [Formula: see text]M). T-1-BHEPA demonstrated selective cytotoxicity against a panel of cancer cell lines, with pronounced activity against MDA-MB-231 (IC 50 [Formula: see text] 11.64 ± 1.0 [Formula: see text]M), and a high selectivity index (SI > 6.7) over normal WI-38 cells. Cell cycle analysis revealed G2/M phase arrest, while apoptosis assays confirmed significant increases in early and late apoptotic populations. These effects were further supported by molecular markers, including elevated caspase-3, upregulation of Bax and downregulation of Bcl-2, consistent with activation of the intrinsic apoptotic pathway. Overall, T-1-BHEPA represents a rationally designed and biologically validated VEGFR-2 inhibitor with promising anticancer efficacy and safety, warranting further preclinical development.

VEGFR-2 inhibitorstheobromine derivativesangiogenesiscancer
مقالوصول مفتوح202410استشهاد· Semantic Scholar

Computational exploration of Picrasma quassioides compounds as CviR-mediated quorum sensing inhibitors against Chromobacterium violaceum

Frontiers in Chemistry · مجلد 12 · 1286675-1286675

Chromobacterium violaceum an opportunistic human pathogenic bacterium, exhibits resistance to conventional antibiotics by exploiting its quorum sensing mechanism to regulate virulence factor expression. In light of this, disrupting the quorum sensing mechanism presents a promising avenue for treating infections caused by this pathogen. The study focused on using the cytoplasmic quorum sensing receptor CviR from C. violaceum as a model target to identify novel quorum sensing inhibitors from P. quassioides through in silico computational approaches. Molecular docking analyses unveiled that several phytochemicals derived from Picrasma quassioides exhibit the potential to inhibit quorum sensing by binding to CviR protein. Notably, the compounds such as Quassidine I (– 8.8 kcal/mol), Quassidine J (– 8.8 kcal/mol), Kumudine B (– 9.1 kcal/mol) and Picrasamide A (– 8.9 kcal/mol) exhibited high docking scores, indicating strong binding affinity to the CviR protein. The native ligand C6-HSL (N-hexanoyl-L-homoserine lactone) as a positive control/co-crystal inhibitor also demonstrated a significant binding energy of—7.7 kcal/mol. The molecular dynamics simulation for 200 ns showed the thermodynamic stability and binding affinity refinement of the top-ranked CviR inhibitor (Kumudine B) with its stable binding and minor fluctuations compared to positive control (C6-HSL). Pharmacokinetic predictions indicated that Kumudine B possesses favourable drug-like properties, which suggest its potential as a drug candidate. The study highlight Kumudine B as a potential agent for inhibiting the CviR protein in C. violaceum. The comprehensive evaluation of Kumudine B provides valuable insights into its pharmacological profiles, facilitating its assessment for diverse therapeutic applications and guiding future research activities, particularly as antibacterial agents for clinical drug development.

Picrasma quassioidesChromobacterium violaceumquorum sensing inhibitionphytochemicals
مقالوصول مفتوح20249استشهاد· Semantic Scholar

Comprehensive analysis of malabar tamarind fruit rind total extract: HPTLC fingerprinting, in-silico exploration of its metabolites for SARS-cov-2 omicron spike protein, antibacterial and antidiabetic potentials with in vitro evaluation of antidiabetic and antioxidant activities

Heliyon · مجلد 10 (15) · e35839-e35839

Malabar tamarind tropical fruit, scientifically known as Garcinia gummi-gutta, is indigenous to Southeast Asia. In this work, the total methanolic extract of the Malabar fruit rind was examined by HPTLC fingerprinting, with quantitative evaluation of the total phenolics and flavonoids. Library of previously reported natural metabolites was utilized to demonstrate their affinity for specific target sites, they were evaluated against Omicron SARS-CoV-2 mainly it's Spike Protein, bacterial tyrosinase, and antidiabetic targets such α-glucosidase, pancreatic lipase and also α-amylase enzymes. The molecular docking revealed that the Guttiferone R possessed the highest binding affinity toward the Omicron Spike Protein with a stable binding mode, −8.67 kcal/mol binding energy and a 1.07 Å RMSD value compared to reference, Azithromycin, which has −8.90 kcal/mol binding affinity and a 1.20 Å RMSD value. On the other hand, the identified polyphenolic compounds; Vitexin, Prunin, Naringin, Hinokiflavone, Kaempherol-3-O-rutinoside, Gallic acid, Naringenin, and Catechin, showed remarkable antidiabetic activity by strong inhibitory activity against α-glucosidase and notable activity against α-amylase compared with acarbose as reference. According to antibacterial activity, the identified compounds showed low affinity with weak activity against screened bacterial strains. In-vitro evaluation of Tamarind antioxidant and antidiabetic potentials, it exhibited a free radical-scavenging potential with 71.75 % retardation and α-glucosidase, α-amylase and pancreatic lipase inhibitor activities with an IC50 of 391.3 ± 26.27, 95.03 ± 0.03 and 0.01043 ± 0.0004 μg/mL, respectively that emphasize the molecular docking study. The findings imply that Malabar tamarind fruit rind possess antioxidant, antidiabetic, antibacterial and antiviral activities.

Garcinia gummi-guttafruit rind extractantiviral activityα-glucosidase inhibition
مقالوصول مغلق20243استشهاد· Semantic Scholar

Repurposing FDA-Approved Drugs as Potential Inhibitors of SARS-CoV-2 PLpro: A Comprehensive Computational Study

Journal of Computational Biophysics and Chemistry · مجلد 23 (09) · 1209-1231

This study explores the repurposing of Food and Drug Administration (FDA)-approved drugs as potential inhibitors of SARS-CoV-2 papain-like protease (PLpro), a critical enzyme for viral replication. Initially, 3009 FDA approved drugs were screened to identify candidates structurally similar to the co-crystallized ligand XT7 in the SARS-CoV-2 PLpro complex (PDB ID: 7LBR). A fingerprint analysis narrowed the selection to the top 5% )150 drugs) most structurally akin to XT7, followed by a more refined structural similarity test that identified the top 1% (30 drugs). Molecular docking studies highlighted several compounds with strong binding affinities to the SARS-CoV-2 PLpro. Notably, Fedratinib exhibited a particularly robust binding energy of [Formula: see text]kcal/mol and was chosen for further investigation. Subsequent molecular dynamics (MD) simulations over 100 ns confirmed the stability and efficacy of Fedratinib’s binding, as evidenced by favorable energetic and dynamic profiles. The molecular mechanics-generalized born surface area (MM-GBSA) calculations corroborated these findings, revealing a binding energy of [Formula: see text]kcal/mol. Additionally, PLIP, ProLIF, and PCAT analyses further validated the stability and interactions of the PLpro-Fedratinib complex observed during the MD simulations. Overall, our results indicate that Fedratinib, an FDA-approved drug, demonstrates promising potential as an inhibitor of SARS-CoV-2 PLpro, warranting further in vitro and in vivo experimental validation as well as potential clinical evaluation.

drug repurposingSARS-CoV-2papain-like proteasePLpro inhibitors
مقالمفتوح (مستودع)20241استشهاد· Semantic Scholar

An evaluation of the precision of computational methods used in drug development initiatives

Journal of Biomolecular Structure and Dynamics · مجلد 44 (5) · 2235-2249

Computational approaches are commonly employed to expedite and provide decision-making for the drug development process. Drug development programs that involve targets without known crystal structures can be quite challenging. In many cases, a viable approach is to generate reliable homology models using the amino acid sequence of the target. This is followed by a series of validation steps, druggable pocket detection, and then moving forward with lead identification and validation. This study commenced by conducting an initial benchmark exercise using a series of computationally designed sequences for steroid-binding proteins. By conducting an unbiased comparison with the released X-ray crystal structures, the homology models that were generated demonstrated reliable outcomes. The aligned homology models showed a root mean square deviation (RMSD) of less than 0.6 Å when compared to the corresponding X-ray structures. Three different methods were used to detect the druggable cavities for comparison, and the identified pockets closely resembled those of the crystal structures. The achievement of near-native pose prediction was made possible by utilizing the comprehensive binding energy function that characterizes the interaction between each pose and the neighboring residues. In order to address the issue of limited correlation between entropy and internal energy in docking, an alternative was devised by incorporating entropy as a post-docking optimization step to enhance the accuracy of ligand binding affinity predictions and improve the overall quality of the results.

homology modelingsteroid binding proteinsmolecular dockingbinding affinity prediction
مقالمفتوح (مستودع)202332استشهاد· Semantic Scholar

In-vitro and computational analysis of Urolithin-A for anti-inflammatory activity on Cyclooxygenase 2 (COX-2)

Saudi Journal of Biological Sciences · مجلد 30 (11) · 103804-103804

Cyclooxygenase 2 (COX-2) participates in the inflammation process by converting arachidonic acid into prostaglandin G2 which increases inflammation, pain and fever. COX-2 has an active site and a heme pocket and blocking these sites stops the inflammation. Urolithin A is metabolite of ellagitannin produced from humans and animals gut microbes. In the current study, Urolithin A showed good pharmacokinetic properties. Molecular docking of the complex of Urolithin A and COX-2 revealed the ligand affinity of -7.97 kcal/mol with the ligand binding sites at TYR355, PHE518, ILE517 and GLN192 with the 4-H bonds at a distance of 2.8Å, 2.3 Å, 2.5 Å and 1.9 Å. The RMSD plot for Urolithin A and COX-2 complex was observed to be constant throughout the duration of dynamics. A total of 3 pair of hydrogen bonds was largely observed on average of 3 simulation positions for dynamics duration of 500ns. The MMPBSA analysis showed that active site amino acids had a binding energy of -22.0368kJ/mol indicating that throughout the simulation the protein of target was bounded by Urolithin A. In-silico results were validated by biological assays. Urolithin A strongly revealed to exhibit anti-inflammatory effect on COX-2 with an IC50 value of 44.04µg/mL. The anti-inflammatory capability was also depicted through reduction of protein denaturation that showed 37.6±0.1 % and 43.2±0.07 % reduction of protein denaturation for BSA and egg albumin respectively at 500µg/mL. The present study, suggests Urolithin A to be an effective anti-inflammatory compound for therapeutic use.

urolithin Acyclooxygenase-2anti-inflammatory activityellagitannin metabolites
مقالمفتوح (مستودع)202314استشهاد· Semantic Scholar

In silico studies and evaluation of in vitro antidiabetic activity of berberine from ethanol seed extract of Coscinium fenestratum (Gaertn.) Colebr

Journal of King Saud University - Science · مجلد 35 (5) · 102666-102666

Tree turmeric or Coscinium fenestratum (Gaertn.) Colebr is a recent focus climber tree for its various potent therapeutic activities. The present study focused on establishing the potent antidiabetic activity of ethanol seed extract of Coscinium fenestratum (CF) after confirmation through in silico molecular docking study. The Soxhlet method was used for the extract preparation using ethanol solvent. Further, phytochemical screening and TLC were performed to detect the compound responsible for the antidiabetic activity. The accessible structure from the plant extract was used in an in-silico docking investigation based on that prediction. For the diabetes docking investigation, the alpha-amylase (HPA) protein with PDB ID: 4X9Y was chosen. After that, alpha-amylase and alpha-glucosidase inhibition assay techniques were also used to test the in vitro antidiabetic activity. Berberine was detected and identified by TLC with an Rf of 0.37 and was found to be responsible for the antidiabetic activity. AutoDock4.2 was employed for in silico study, and the binding energy of berberine was −7.84, demonstrating the significant antidiabetic properties of the ethanol extract from CF seeds. The ethanol seed extract of CF may have an anti-diabetic effect because of the presence of berberine in the extract as one of the phytochemicals. However, additional research is required to ascertain the potential synergistic or antagonistic effects amongst various CF seed extract constituents.

Coscinium fenestratumberberineantidiabetic activityseed extract
مقالوصول مغلق20237استشهاد· Semantic Scholar

A novel thieno[2,3‐d]pyrimidine derivative inhibiting vascular endothelial growth factor receptor‐2: A story of computer‐aided drug discovery

Drug Development Research · مجلد 84 (6) · 1247-1265

Abstract Following the pharmacophoric features of vascular endothelial growth factor receptor 2 (VEGFR‐2) inhibitors, a novel thieno[2,3‐d]pyrimidine derivative has been designed and its activity against VEGFR‐2 has been demonstrated by molecular docking studies that showed an accurate binding mode and an excellent binding energy. Furthermore, the recorded binding was confirmed by a series of molecular dynamics simulation studies, which also revealed precise energetic, conformational, and dynamic changes. Additionally, molecular mechanics with generalized Born and surface area solvation and polymer‐induced liquid precursors studies were conducted and verified the results of the MD simulations. Next, in silico absorption, distribution, metabolism, excretion, and toxicity studies have also been conducted to examine the general drug‐like nature of the designed candidate. According to the previous results, the thieno[2,3‐d]pyrimidine derivative was synthesized. Fascinatingly, it inhibited VEGFR‐2 (IC50 = 68.13 nM) and demonstrated strong inhibitory activity toward human liver (HepG2), and prostate (PC3) cell lines with IC50 values of 6.60 and 11.25 µM, respectively. As well, it was safe and showed a high selectivity index against normal cell lines (WI‐38). Finally, the thieno[2,3‐d]pyrimidine derivative arrested the growth of the HepG2 cells at the G2/M phase inducing both early and late apoptosis. These results were further confirmed through the ability of the thieno[2,3‐d]pyrimidine derivative to induce significant changes in the apoptotic genes levels of caspase‐3, caspase‐9, Bcl‐2 associated X‐protein, and B‐cell lymphoma 2.

thieno[2,3-d]pyrimidine derivativesVEGFR-2 inhibitorsvascular endothelial growth factor receptor 2anticancer drug design
مقالمفتوح (مستودع)20234استشهاد· Semantic Scholar

Synthesis and anti-tubercular evaluation of some novel (E)-5-(4-(benzylidene amino) phenyl)-1,3,4-oxadiazole-2-thiol derivatives

Journal of King Saud University - Science · مجلد 35 (6) · 102737-102737

Tuberculosis remains a ninth global health cause affecting millions of people. The susceptibility and resistance caused by first and second-line drugs have not changed for decades. There is a need to develop novel drugs with better pharmacological profiles. In this study, a series of (E)-5-(4-(benzylidene amino) phenyl)-1,3,4-oxadiazole-2-thiol derivatives were synthesized, docked, and ADMET studies were performed. Based on binding affinity, the compounds were evaluated for their ability to inhibit the M. tuberculosis H37Rv strain. The compounds showed binding energy between −8.2 and −10.0 Kcal/mol. Molecular simulations benefited the representation of the actual biological conditions with a significant outcome. The compound 5-(4-{(E)-[(2-nitrophenyl) methylidene] amino} phenyl)-1,3,4-oxadiazole-2-thiol (R4) showed the best binding −10.0 Kcal/mol, MIC of 0.8 µg/ml, the IC50 value of 49.01 and the Selectivity Index of 61.33. The synthesized compounds were evaluated for anti-mycobacterial activity against M. tuberculosis (H37Rv) using MABA assay and compared with the standards; R3 and R4 were sensitive at 0.8 µg/ml. Among the designed compounds 5-(4-{(E)-[(2-nitrophenyl)methylidene]amino}phenyl)-1,3,4-oxadiazole-2-thiol showed the best activity with higher IC50 values. As a result, molecular hit can be good lead for further development for tuberculosis treatment.

tuberculosisanti-tubercular agentsMycobacterium tuberculosis H37Rvmolecular docking
مقالوصول مفتوح20231استشهاد· Semantic Scholar

Phytoconstituents of Butterbur ( P. japonicus ), their metabolic pathway and ability to modulate bone morphogenic protein (BMP) signaling

Journal of Plant Interactions · مجلد 18 (1)

A library of natural sesquiterpene and phenolic compounds from Petasites japonicus are being investigated through different computational techniques to study their ability to target BMP. Lipinski rule, ADMET, molecular docking studies and metabolism were used to reach promising candidates with proposed activity against BMP. Four sesquiterpenes (kablicin, petisinol, bakkenolide D and bakkenolide IIIa) and four phenolic compounds exhibited drug-like properties (caffeic acid, petasiphenol, petasitesin A and petasitesin B), so they deserve further clinical exploration as bone loss modulators. The phenolic compounds specially fukinolic acid and petasiphenol showed lower binding energy with both BMPRIA and BMPRII than Icariin agonist and sesquiterpenes. Bakkenolide IIIa showed dual potential on both BMPRIA and BMPRII with binding energies equal – 7.82 and – 9.9 Kcal/mol respectively, which is more better score than Betulinic acid agonist. This research is focusing on plant-human interactions and exploring the ability of plant constituents to modulate a human protein such as BMP.

Petasites japonicusbutterbursesquiterpenesphenolic compounds
مقالوصول مفتوح2022114استشهاد· Semantic Scholar

Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects

Molecules · مجلد 27 (14) · 4606-4606

A nicotinamide-based derivative was designed as an antiproliferative VEGFR-2 inhibitor with the key pharmacophoric features needed to interact with the VEGFR-2 catalytic pocket. The ability of the designed congener ((E)-N-(4-(1-(2-(4-benzamidobenzoyl)hydrazono)ethyl)phenyl)nicotinamide), compound 10, to bind with the VEGFR-2 enzyme was demonstrated by molecular docking studies. Furthermore, six various MD simulations studies established the excellent binding of compound 10 with VEGFR-2 over 100 ns, exhibiting optimum dynamics. MM-GBSA confirmed the proper binding with a total exact binding energy of −38.36 Kcal/Mol. MM-GBSA studies also revealed the crucial amino acids in the binding through the free binding energy decomposition and declared the interactions variation of compound 10 inside VEGFR-2 via the Protein–Ligand Interaction Profiler (PLIP). Being new, its molecular structure was optimized by DFT. The DFT studies also confirmed the binding mode of compound 10 with the VEGFR-2. ADMET (in silico) profiling indicated the examined compound’s acceptable range of drug-likeness. The designed compound was synthesized through the condensation of N-(4-(hydrazinecarbonyl)phenyl)benzamide with N-(4-acetylphenyl)nicotinamide, where the carbonyl group has been replaced by an imine group. The in-vitro studies were consonant with the obtained in silico results as compound 10 prohibited VEGFR-2 with an IC50 value of 51 nM. Compound 10 also showed antiproliferative effects against MCF-7 and HCT 116 cancer cell lines with IC50 values of 8.25 and 6.48 μM, revealing magnificent selectivity indexes of 12.89 and 16.41, respectively.

nicotinamide derivativesVEGFR-2 inhibitorsantiproliferative agentsanticancer agents
مقالوصول مفتوح202253استشهاد· Semantic Scholar

The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches

Processes · مجلد 10 (7) · 1391-1391

Corresponding to the reported features of anti-VEGFR-2-approved compounds, a new 1H-indole derivative (compound 7) was designed. The inhibitory potential of the designed compound was revealed via a molecular docking study that showed the appropriate binding. Then, MD simulation (six studies) over a period of 100 ns was performed to confirm the precise binding and optimum energy. Additionally, MM-GBSA reaffirmed the perfect binding, exhibiting a total precise energy of −40.38 Kcal/Mol. The MM-GBSA experiments named the essential amino acids in the protein–ligand interaction, employing the binding energy decomposition and revealing the diversity of interactions of compound 7 inside the VEGFR-2 enzyme. As compound 7 is new, DFT experiments were utilized for molecular structure optimization. Additionally, the DFT results validated the coherent interaction of compound 7 with the VEGFR-2 enzyme. A good value of drug-likeness of compound 7 was acknowledged via in silico ADMET studies. Interestingly, the experimental in vitro prohibitory potential of compound 7 was better than that of sorafenib, demonstrating an IC50 value of 25 nM. Notably, the strong inhibitory effects of compound 10 against two cancer cell lines (MCF-7 and HCT 116) were established with IC50 values of 12.93 and 11.52 μM, disclosing high selectivity indexes of 6.7 and 7.5, respectively.

VEGFR-2 inhibitionanticancer activitymolecular dockingmolecular dynamics simulation
مقالوصول مغلق202250استشهاد· Semantic Scholar

In silico, in vitro VEGFR-2 inhibition, and anticancer activity of a 3-(hydrazonomethyl)naphthalene-2-ol derivative

Journal of Biomolecular Structure and Dynamics · مجلد 41 (16) · 7986-8001

In agreement with the general features of VEGFR-2 inhibitors, a new naphthalene analog (compound 7) has been designed and synthesized. The inhibitory potential of compound 7 was indicated by the proper binding and the perfect energy of −21.10 kcal/mol compared to sorafenib (−21.22) in the molecular docking studies. Next, six MD simulation studies over 100 ns (RMSD, RMSF, SASA, RoG, hydrogen bonding, and distance between the center of mass) confirmed the accurate interaction of compound 7 with the catalytic pocket of VEGFR-2. Similarly, an MM-GBSA established proper binding showing an exact total binding energy of −36.95 ± 3.03 kcal/Mol. Additionally, the MM-GBSA experiment indicated the vital amino acids in the binding process. Types and number of interactions of compound 7 with catalytic pocket of VEGFR-2 were determined through Protein-Ligand Interaction Profiler (PLIP). As a new compound, the DFT was employed to optimize the molecular structure of compound 7. The DFT experiments also verified the interaction features of compound 7 with the VEGFR-2 active site. In silico ADMET experiments revealed the general drug-likeness of compound 7. Fascinatingly, the in vitro examinations were consistent with the in silico experiments as compound 7 inhibited the VEGFR-2 enzyme with an IC50 value of 37 nM. Captivatingly, compound 7 inhibited both MCF-7 and HCT 116 cancer cells exhibiting IC50 values of 10.56 and 7.07 µM exhibiting excellent selectivity indexes of 9.04 and 13.50, respectively.Communicated by Ramaswamy H. Sarma

VEGFR-2 inhibitionnaphthalene derivativesanticancer activitymolecular docking